Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study

Risankizumab is a humanized monoclonal antibody that binds the p19 subunit of interleukin-23. It is approved for treatment of moderate-severe chronic plaque psoriasis. This retrospective study included 66 consecutive adults with moderate-to-severe psoriasis vulgaris treated with risankizumab in mono...

Full description

Saved in:
Bibliographic Details
Main Authors: Riccardo G. Borroni (Author), Piergiorgio Malagoli (Author), Luigi Gargiulo (Author), Mario Valenti (Author), Giulia Pavia (Author), Paola Facheris (Author), Emanuela Morenghi (Author), Isotta Giunipero di Corteranzo (Author), Alessandra Narcisi (Author), Michela Ortoncelli (Author), Paolo Dapavo (Author), Antonio Costanzo (Author)
Format: Book
Published: Medical Journals Sweden, 2021-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items